Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome

Subgroup analysis of JAPAN-ACS study

Taiki Ohashi, Rei Shibata, Takeshi Morimoto, Masaaki Kanashiro, Hideki Ishii, Satoshi Ichimiya, Takafumi Hiro, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Takeshi Kimura, Hiroyuki Daida, Toyoaki Murohara, Masunori Matsuzaki

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: The Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) study demonstrated that aggressive lipid-lowering therapy with a statin resulted in a significant regression of coronary atherosclerotic plaques in patients with ACS. Adiponectin is an adipocyte-derived protein with anti-atherogenic properties. Here, we investigated the association between adiponectin levels and the change in the plaque volume in ACS patients. Methods: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken, followed by the initiation of statin treatment, in 238 patients with ACS. Follow-up IVUS was performed between 8 and 12 months after the PCI. The percent change in the plaque volume (%PV) in a non-culprit coronary artery segment was evaluated. The serum adiponectin and lipid parameters were measured both at baseline and at the follow-up. Results: At baseline, adiponectin was correlated positively with HDL-cholesterol and negatively correlated with triglyceride, but no correlation was observed with the PV. Adiponectin levels increased significantly from 7.8 ± 4.6 μg/mL at baseline to 10.3 ± 6.9 μg/mL at the 8-12 months follow-up. The increase in adiponectin was also associated with an increase of HDL-cholesterol and decrease of triglyceride, however, no significant correlation was observed with the %PV. A significantly higher incidence of major adverse cardiac events (MACE) was observed in patients with hypo-adiponectinemia at baseline. A multiple logistic regression analysis identified adiponectin as a significant independent predictor of MACE. Conclusion: Adiponectin levels measured after PCI could serve as a marker of MACE in patients with ACS.

Original languageEnglish
Pages (from-to)237-242
Number of pages6
JournalAtherosclerosis
Volume212
Issue number1
DOIs
Publication statusPublished - 01-09-2010

Fingerprint

Adiponectin
Acute Coronary Syndrome
Japan
Lipids
Percutaneous Coronary Intervention
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Therapeutics
HDL Cholesterol
Triglycerides
pitavastatin
Atorvastatin Calcium
Atherosclerotic Plaques
Adipocytes
Coronary Vessels
Logistic Models
Regression Analysis
Incidence
Serum

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Ohashi, Taiki ; Shibata, Rei ; Morimoto, Takeshi ; Kanashiro, Masaaki ; Ishii, Hideki ; Ichimiya, Satoshi ; Hiro, Takafumi ; Miyauchi, Katsumi ; Nakagawa, Yoshihisa ; Yamagishi, Masakazu ; Ozaki, Yukio ; Kimura, Takeshi ; Daida, Hiroyuki ; Murohara, Toyoaki ; Matsuzaki, Masunori. / Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome : Subgroup analysis of JAPAN-ACS study. In: Atherosclerosis. 2010 ; Vol. 212, No. 1. pp. 237-242.
@article{08ecb507c7024ed8a865a04b1a36aeba,
title = "Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: Subgroup analysis of JAPAN-ACS study",
abstract = "Objective: The Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) study demonstrated that aggressive lipid-lowering therapy with a statin resulted in a significant regression of coronary atherosclerotic plaques in patients with ACS. Adiponectin is an adipocyte-derived protein with anti-atherogenic properties. Here, we investigated the association between adiponectin levels and the change in the plaque volume in ACS patients. Methods: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken, followed by the initiation of statin treatment, in 238 patients with ACS. Follow-up IVUS was performed between 8 and 12 months after the PCI. The percent change in the plaque volume ({\%}PV) in a non-culprit coronary artery segment was evaluated. The serum adiponectin and lipid parameters were measured both at baseline and at the follow-up. Results: At baseline, adiponectin was correlated positively with HDL-cholesterol and negatively correlated with triglyceride, but no correlation was observed with the PV. Adiponectin levels increased significantly from 7.8 ± 4.6 μg/mL at baseline to 10.3 ± 6.9 μg/mL at the 8-12 months follow-up. The increase in adiponectin was also associated with an increase of HDL-cholesterol and decrease of triglyceride, however, no significant correlation was observed with the {\%}PV. A significantly higher incidence of major adverse cardiac events (MACE) was observed in patients with hypo-adiponectinemia at baseline. A multiple logistic regression analysis identified adiponectin as a significant independent predictor of MACE. Conclusion: Adiponectin levels measured after PCI could serve as a marker of MACE in patients with ACS.",
author = "Taiki Ohashi and Rei Shibata and Takeshi Morimoto and Masaaki Kanashiro and Hideki Ishii and Satoshi Ichimiya and Takafumi Hiro and Katsumi Miyauchi and Yoshihisa Nakagawa and Masakazu Yamagishi and Yukio Ozaki and Takeshi Kimura and Hiroyuki Daida and Toyoaki Murohara and Masunori Matsuzaki",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.atherosclerosis.2010.05.005",
language = "English",
volume = "212",
pages = "237--242",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

Ohashi, T, Shibata, R, Morimoto, T, Kanashiro, M, Ishii, H, Ichimiya, S, Hiro, T, Miyauchi, K, Nakagawa, Y, Yamagishi, M, Ozaki, Y, Kimura, T, Daida, H, Murohara, T & Matsuzaki, M 2010, 'Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: Subgroup analysis of JAPAN-ACS study', Atherosclerosis, vol. 212, no. 1, pp. 237-242. https://doi.org/10.1016/j.atherosclerosis.2010.05.005

Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome : Subgroup analysis of JAPAN-ACS study. / Ohashi, Taiki; Shibata, Rei; Morimoto, Takeshi; Kanashiro, Masaaki; Ishii, Hideki; Ichimiya, Satoshi; Hiro, Takafumi; Miyauchi, Katsumi; Nakagawa, Yoshihisa; Yamagishi, Masakazu; Ozaki, Yukio; Kimura, Takeshi; Daida, Hiroyuki; Murohara, Toyoaki; Matsuzaki, Masunori.

In: Atherosclerosis, Vol. 212, No. 1, 01.09.2010, p. 237-242.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome

T2 - Subgroup analysis of JAPAN-ACS study

AU - Ohashi, Taiki

AU - Shibata, Rei

AU - Morimoto, Takeshi

AU - Kanashiro, Masaaki

AU - Ishii, Hideki

AU - Ichimiya, Satoshi

AU - Hiro, Takafumi

AU - Miyauchi, Katsumi

AU - Nakagawa, Yoshihisa

AU - Yamagishi, Masakazu

AU - Ozaki, Yukio

AU - Kimura, Takeshi

AU - Daida, Hiroyuki

AU - Murohara, Toyoaki

AU - Matsuzaki, Masunori

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Objective: The Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) study demonstrated that aggressive lipid-lowering therapy with a statin resulted in a significant regression of coronary atherosclerotic plaques in patients with ACS. Adiponectin is an adipocyte-derived protein with anti-atherogenic properties. Here, we investigated the association between adiponectin levels and the change in the plaque volume in ACS patients. Methods: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken, followed by the initiation of statin treatment, in 238 patients with ACS. Follow-up IVUS was performed between 8 and 12 months after the PCI. The percent change in the plaque volume (%PV) in a non-culprit coronary artery segment was evaluated. The serum adiponectin and lipid parameters were measured both at baseline and at the follow-up. Results: At baseline, adiponectin was correlated positively with HDL-cholesterol and negatively correlated with triglyceride, but no correlation was observed with the PV. Adiponectin levels increased significantly from 7.8 ± 4.6 μg/mL at baseline to 10.3 ± 6.9 μg/mL at the 8-12 months follow-up. The increase in adiponectin was also associated with an increase of HDL-cholesterol and decrease of triglyceride, however, no significant correlation was observed with the %PV. A significantly higher incidence of major adverse cardiac events (MACE) was observed in patients with hypo-adiponectinemia at baseline. A multiple logistic regression analysis identified adiponectin as a significant independent predictor of MACE. Conclusion: Adiponectin levels measured after PCI could serve as a marker of MACE in patients with ACS.

AB - Objective: The Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) study demonstrated that aggressive lipid-lowering therapy with a statin resulted in a significant regression of coronary atherosclerotic plaques in patients with ACS. Adiponectin is an adipocyte-derived protein with anti-atherogenic properties. Here, we investigated the association between adiponectin levels and the change in the plaque volume in ACS patients. Methods: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken, followed by the initiation of statin treatment, in 238 patients with ACS. Follow-up IVUS was performed between 8 and 12 months after the PCI. The percent change in the plaque volume (%PV) in a non-culprit coronary artery segment was evaluated. The serum adiponectin and lipid parameters were measured both at baseline and at the follow-up. Results: At baseline, adiponectin was correlated positively with HDL-cholesterol and negatively correlated with triglyceride, but no correlation was observed with the PV. Adiponectin levels increased significantly from 7.8 ± 4.6 μg/mL at baseline to 10.3 ± 6.9 μg/mL at the 8-12 months follow-up. The increase in adiponectin was also associated with an increase of HDL-cholesterol and decrease of triglyceride, however, no significant correlation was observed with the %PV. A significantly higher incidence of major adverse cardiac events (MACE) was observed in patients with hypo-adiponectinemia at baseline. A multiple logistic regression analysis identified adiponectin as a significant independent predictor of MACE. Conclusion: Adiponectin levels measured after PCI could serve as a marker of MACE in patients with ACS.

UR - http://www.scopus.com/inward/record.url?scp=77956228825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956228825&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2010.05.005

DO - 10.1016/j.atherosclerosis.2010.05.005

M3 - Article

VL - 212

SP - 237

EP - 242

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -